Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB.

Blood. 2009 Apr 2;113(14):3154-60. doi: 10.1182/blood-2008-07-166439. Epub 2008 Dec 18.

2.
3.

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E.

Arthritis Rheum. 2008 Nov;58(11):3309-18. doi: 10.1002/art.23992.

4.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.

5.

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB.

N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.

6.

Fostamatinib: First Global Approval.

Markham A.

Drugs. 2018 Jun;78(9):959-963. doi: 10.1007/s40265-018-0927-1. Review.

PMID:
29869203
7.

Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.

Niscola P, Scaramucci L, Giovannini M.

Immunotherapy. 2018 Jan;10(1):5-7. doi: 10.2217/imt-2017-0141. No abstract available.

PMID:
29192558
8.

Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?

Gómez-Puerta JA, Bosch X.

Nat Rev Rheumatol. 2011 Mar;7(3):134-6. doi: 10.1038/nrrheum.2011.8. Epub 2011 Feb 8.

PMID:
21304505
9.

Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.

Scott DL.

Drugs. 2011 Jun 18;71(9):1121-32. doi: 10.2165/11591480-000000000-00000. Review.

PMID:
21711059
10.
11.

The status of fostamatinib in the treatment of rheumatoid arthritis.

Morales-Torres J.

Expert Rev Clin Immunol. 2012 Sep;8(7):609-15. doi: 10.1586/eci.12.63.

PMID:
23078058
12.

Fostamatinib for persistent/chronic adult immune thrombocytopenia.

Newland A, Lee EJ, McDonald V, Bussel JB.

Immunotherapy. 2018 Jan;10(1):9-25. doi: 10.2217/imt-2017-0097. Epub 2017 Oct 2. Review.

13.

Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.

Boers M.

Arthritis Rheum. 2011 Feb;63(2):329-30. doi: 10.1002/art.30109. No abstract available.

14.

Syk inhibitors.

Chihara K, Kimura Y, Honjo C, Takeuchi K, Sada K.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):197-202. Review. English, Japanese.

PMID:
23994797
15.

Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.

Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR.

Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77. Epub 2007 Mar 31.

PMID:
17490694
16.

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.

Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T.

J Dermatol Sci. 2014 Jun;74(3):214-21. doi: 10.1016/j.jdermsci.2014.02.008. Epub 2014 Mar 12.

PMID:
24679982
17.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW.

Eur J Cancer. 2016 Feb;54:11-17. doi: 10.1016/j.ejca.2015.10.005. Epub 2015 Dec 18.

PMID:
26707592
18.

Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Okamoto H, Kobayashi A.

N Engl J Med. 2011 Jan 6;364(1):83-4; author reply 84. doi: 10.1056/NEJMc1012187. No abstract available.

PMID:
21208113
19.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.

Blood. 2008 Aug 15;112(4):999-1004. doi: 10.1182/blood-2008-01-131029. Epub 2008 May 7.

20.

Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.

Nijjar JS, Tindell A, McInnes IB, Siebert S.

Rheumatology (Oxford). 2013 Sep;52(9):1556-62. doi: 10.1093/rheumatology/ket225. Epub 2013 Jul 16. Review.

PMID:
23861534

Supplemental Content

Support Center